Limitations in contrast enhancement standardization indicate unenhanced diffusion measurement should be preferred.
Using a gadolinium-based contrast agent (GBCA) with diffusion-tensor imaging (DTI) does not change the accuracy of breast cancer diagnosis, according to a new study.
In an article published in the American Journal of Roentgenology, investigators from Princess Margaret Cancer Center in Toronto, Canada, discussed the impact of GBCA with 3T breast MRI.
“Diagnostic accuracy using DTI was equivalent before and after GBCA administration, despite a change in the values of the DTI parameters,” wrote the team, led by Anabel M. Scaranelo, M.D., Ph.D., assistant professor of radiology. “However, the limitations in standardization of contrast enhancement implies that unenhanced diffusion measurements should be preferred.”
To make this determination, the team conducted a pilot study with 26 women, ranging from ages 37 to 69, who had BI-RADS scores of 0, 4, 5, and 6. The participants were scheduled for diagnostic breast 3T MRI and were scanned twice using the same DTI sequence both before and immediately after the breast dynamic contrast-enhanced MRI.
The team used dedicated DTI software to conduct quantitative image analysis to produce parametric DTI maps of each directional diffusion co-efficient (DDC), mean diffusivity, and maximal anisotropy of the lesions and normal tissue. They, then, used statistical tests to evaluate the color maps and compare the lesion DTI parameters both before and after GBCA administration.
According to the analysis conducted by Scaranelo’s team, 58 percent of the women were diagnosed with cancer – 13 women had infiltrating ductal carcinoma and two had ductal carcinoma in situ. The remaining 42 percent had benign or normal results. All of the cancers could be visually identified in the DDCλ1 maps both before and after GBCA use. The mean cancer size of 15.3 mm prior to use, and it was not statistically significantly different afterwards, the team said.
However, after GBCA use, Scaranelo said, the cancers did demonstrate statistically significantly lower DDCs, mean diffusivity, and b0 intentsity. They also exhibited no change in maximal anisotropy when evaluated against pre-GBCA administration. In fact, the mean AUC values both before and after GBCA administration were not statistically significantly different for all parameters other than λ3.
Based on these findings, the team determined there was a statistically significant reduction in the DDCs of breast cancer after dynamic contrast enhancement. As a result, they said, the enhancement leads “to equivalent or increased conspicuity of the cancer lesions in the visual assessment by the radiologist.”
Given that the accuracy of breast cancer detection was not significantly different for unenhanced or contrast-enhanced DTI datasets – and because DTI parameters are intrinsic tissue characteristics – Scaranelo said DTI use prior to dynamic contrast enhancement should be fully standardized.
“The contrast-enhanced DTI parameters are less amenable to standardization because their values depend on the type and dose of contrast agent and on variations in the contrast agent dynamics among the various types of breast cancers,” she explained, noting that the lack of contrast-enhanced DTI standardization supports the preference for unenhanced diffusion measurements.
Stay at the forefront of radiology with the Diagnostic Imaging newsletter, delivering the latest news, clinical insights, and imaging advancements for today’s radiologists.
The Reading Room Podcast: A Closer Look at Remote MRI Safety, Part 2
July 25th 2025In the second of a multi-part podcast episode, Emanuel Kanal, M.D. and Tobias Gilk, MRSO, MRSE, share their perspectives on remote MRI safety protocols for ensuring screening accuracy and adherence to conditional implant guidelines as well as a rapid and effective response to adverse events.
Study Reveals Significant Prevalence of Abnormal PET/MRI and Dual-Energy CT Findings with Long Covid
July 22nd 2025In a prospective study involving nearly 100 patients with Long Covid, 57 percent of patients had PET/MRI abnormalities and 90 percent of the cohort had abnormalities on dual-energy CT scans.
The Reading Room Podcast: Current and Emerging Insights on Abbreviated Breast MRI, Part 2
July 23rd 2025In the second part of a multi-part podcast episode, Stamatia Destounis, MD, Emily Conant, MD and Habib Rahbar, MD, discuss key sequences for abbreviated breast MRI and how it stacks up to other breast cancer screening modalities.
Stroke MRI Study Assesses Impact of Motion Artifacts Upon AI and Radiologist Lesion Detection
July 16th 2025Noting a 7.4 percent incidence of motion artifacts on brain MRI scans for suspected stroke patients, the authors of a new study found that motion artifacts can reduce radiologist and AI accuracy for detecting hemorrhagic lesions.